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Structural and biochemical insights 
of CypA and AIF interaction
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The Cyclophilin A (CypA)/Apoptosis Inducing Factor (AIF) complex is implicated in the DNA degradation 
in response to various cellular stress conditions, such as oxidative stress, cerebral hypoxia-ischemia 
and traumatic brain injury. The pro-apoptotic form of AIF (AIF(Δ1-121)) mainly interacts with CypA 
through the amino acid region 370–394. The AIF(370-394) synthetic peptide inhibits complex formation 
in vitro by binding to CypA and exerts neuroprotection in a model of glutamate-mediated oxidative 
stress. Here, the binding site of AIF(Δ1-121) and AIF(370-394) on CypA has been mapped by NMR 
spectroscopy and biochemical studies, and a molecular model of the complex has been proposed. We 
show that AIF(370-394) interacts with CypA on the same surface recognized by AIF(Δ1-121) protein and 
that the region is very close to the CypA catalytic pocket. Such region partially overlaps with the binding 
site of cyclosporin A (CsA), the strongest catalytic inhibitor of CypA. Our data point toward distinct 
CypA structural determinants governing the inhibitor selectivity and the differential biological effects 
of AIF and CsA, and provide new structural insights for designing CypA/AIF selective inhibitors with 
therapeutic relevance in neurodegenerative diseases.
Key players of programmed cell death (PCD) signalling pathways also contribute to acute neurological insults 
such as hypoxic-ischemic brain damage (HI), traumatic brain injury (TBI) and stroke1, 2. A critical step of the 
apoptotic cascade is the permeabilization of the outer mitochondrial membrane (OMM), mediated by pro- and 
anti-apoptotic Bcl-2 family proteins, culminating in the release of soluble intermembrane proteins from mito-
chondria1–3. Once released into the cytosol, these mitochondrial proteins activate caspase-dependent and/or 
caspase-independent cell death pathways4. Caspase-dependent cell death, mediated by the release of cytochrome 
C from mitochondria, apoptosome formation and caspase activation, has been studied in detail5. Instead, very 
little is known about the contribution of caspase-independent mechanisms to neuronal cell death in neurodegen-
erative diseases6.
Apoptosis-Inducing Factor (AIF) is one of the pro-apoptotic mitochondria-released factors, which contributes 
to apoptotic nuclear DNA damage in a caspase-independent way6.
AIF is an old mitochondrial flavoprotein implicated in embryonic development and cardiac cell survival7. 
In healthy mitochondria, the mature form of AIF (AIF(Δ1-101)), containing two FAD-binding domains (res-
idues 122–262 and 400–477), a NADH-binding domain (residues 263–399) and a C-terminal domain (resi-
dues 478–613), is anchored to the inner mitochondrial membrane (IMM), where it plays a bioenergetic role by 
regulating mainly the activity of the mitochondrial respiratory chain complex I7, 8. Furthermore, AIF induces 
cell-death in response to various cellular stress conditions such as oxidative stress9, DNA damage10, cerebral 
hypoxia-ischemia11 and TBI lethal mechanisms12. The multiple intracellular stress pathways at the end converge 
on mitochondria depolarization and fragmentation1 and the consequent release of the apoptogenic form of AIF 
(AIF(Δ1-121)) from mitochondria to nuclei, where it triggers chromatin condensation and large scale DNA 
fragmentation through a mechanism independent of caspases activation9–12. The pro-apoptotic function of AIF is 
tightly regulated in neurons, and involves its association with the Cyclophilin A (CypA) protein13, 14.
CypA is an abundant, ubiquitously expressed protein, first discovered as an intracellular receptor of the immu-
nosuppressive drug cyclosporin A (CsA)15. CypA exerts peptidyl-prolyl-isomerase activity in vitro, suggesting 
that it can affect conformational changes of other proteins in cells; however its function is largely unknown15. 
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Moreover, several evidence suggested its involvement in key processes underling human pathologies16. Beyond 
the different roles played into different cellular contexts, CypA promotes the lethal action of AIF by mediating 
its nuclear translocation and/or its DNase activity, depending on the cell type and/or the apoptotic insult13, 14, 17. 
Loss or down-regulation of AIF and CypA, combined with caspases inhibition, has been associated with additive 
neuroprotection effects in several in vivo animal models, through a not yet clarified mechanism12–14.
Despite many evidences indicate the complex as a key player of neuronal loss pathways, very little is known 
about the molecular interactions between the two targets, since the three-dimensional (3D) complex structure 
is not available so far. To date, only a molecular docking model, which fits with mutational studies, has been 
proposed by Candé and coworkers13. In this model, AIF contributes to the interface with α11 (P345-R358), 
with β-strands (T328-F334, V361-N366, R387-A397) and several turns (E359-G360, A367-S371, K382-G386) 
that form together a β-sheet bulge. CypA contributes to the interface with α3 (M136-G146), the following turn 
and the β-strand β8 (S147-G150), as well as part of its central β-barrell comprising β3-β4 (R55-Q63), β4-β5 
(H92-A101) and β6-α2 (Q111-T119). On the basis of this model, we have identified the peptide AIF(370-394) 
as the minimal region of AIF that interacts with CypA. However, other regions supposed to be involved in the 
mutual interaction, have failed to completely validate the model13.
The peptide AIF(370-394) identified is able to inhibit the AIF(Δ1-121)/CypA complex formation in vitro 
by binding CypA with a relatively affinity in the low micromolar range. Moreover, the delivery of the pep-
tide in neuronal cells provided a pronounced neuroprotection in a model of AIF(Δ1-121)/CypA-mediated 
glutamate-induced cell death18, by blocking the nuclear translocation of the two proteins18. These findings further 
demonstrated that the direct inhibition of the AIF(Δ1-121)/CypA complex formation has a therapeutic relevance 
for neurodegenerative diseases treatment and showed that AIF(370-394) may represent a valid ligand model to 
study the interaction between AIF and CypA and to design new and more effective inhibitors.
On this framework, in the present work, the AIF(Δ1-121) and AIF(370-394) interacting regions on CypA 
have been mapped by a combination of Nuclear Magnetic Resonance (NMR) spectroscopy and mass spectrome-
try (MS) and the minimal CypA-region mainly involved in the interaction with AIF has been identified through 
binding assays of representative CypA peptides. Isothermal titration calorimetry (ITC), has been also used to 
assess the interactions observed by NMR and to compare the binding mechanism of AIF(370-394) with that of 
the known inhibitor CsA. Finally, data have been used to build a docking model of the AIF/CypA interaction. 
Overall, our study identifies a hydrophilic CypA surface recognized by AIF(Δ1-121), as well as by AIF(370-394), 
that represents a new and selective druggable region of CypA.
Results
Mapping of AIF(Δ1-121) binding site on CypA by NMR-CSP studies. To identify CypA residues 
involved in the interaction with AIF(Δ1-121), we performed a NMR Chemical shift perturbation (CSP) analysis 
by acquiring 2D [15N, 1H] HSQC spectra of 15N-labeled CypA in the absence and presence of increasing concen-
trations of unlabeled AIF(Δ1-121). Upon addition of AIF(Δ1-121), a dose-response reduction of cross-peaks 
intensities was observed in the 2D [15N, 1H] HSQC spectrum of CypA. The cross-peaks virtually disappeared 
upon addition of a stoichiometric amount of AIF(Δ1-121) (ratio 1:1). This behavior is in agreement with the for-
mation of a large complex, in a slow-intermediate exchange regime between free and bound protein, as expected 
from the KD value in the low micromolar range (0.9 μM)18. At sub-stoichiometric levels of AIF(Δ1-121) (until 
a ratio 1:0.6, CypA:AIF(Δ1-121)), differential HSQC cross-peaks intensity reduction provided indications on 
the residues of CypA involved in the interaction with AIF(Δ1-121) (Fig. 1A). Intensity changes of amide signals 
(Ibound/Ifree) following protein addition are plotted in the histogram shown in Fig. 1B. The mean value of Ibound/Ifree 
was ~0.4, indicating that the fraction of bound protein is ~0.6, in agreement with the 1:0.6 CypA:AIF(Δ1-121) 
ratio and the 1:1 stoichiometry of the complex18. Residues having the largest intensity reduction (higher than 
the mean value plus 1 SD) are located in the loop β1-β2 (D13, G14), sheet β2 (R19), loop α1-β3 (G47, S51), loop 
β4-β5 (F67, R69, T73, G74, K76, I78, K82, E86, G96), sheet β5 (M100), loop β5-β6 (A101, N102, S110, Q111), 
sheet β6 (C115), loop β6-α2 (T119), sheet β7 (K133), helix α3 (M136, N137), loop α3-β8 (S153), sheet β8 (Q163). 
Residues having ΔI included between 0.5 and 1 SD over the mean value, are located in the sheet β1 (V12), helix 
α1 (K31, F36), loops β3-β4 (G59), β4-β5 (D66, G75, F88) and β5-β6 (A103, T107), sheet β6 (F113), helix α3 
(V139, A141, R144), loop α3-β8 (T152), sheet β8 (T157). Mapping of these residues onto the structure of CypA 
protein (Fig. 1C and D) reveals that AIF(Δ1-121) binding affects a rather contiguous and extensive surface, 
constituted essentially by the long β4-β5 loop, the β5 and β6 sheets and their connecting loops (Fig. 1C and D).
Mapping of the AIF(370-394) ligand-binding site on CypA by NMR-CSP studies. To further 
understand the basis of the specific interaction between CypA and AIF(Δ1-121), we performed a CSP analysis 
following the HN chemical shift variations of the 15N-CypA signals induced by addition of AIF(370-394).
A number of resonances in the 2D 1H -15N-HSQC spectrum exhibited continuous and significant chemical 
shift variations following the titration of 15N-CypA with AIF(370-394) up to a 10-fold molar excess. Most changes 
occurred in the intermediate exchange regime on the NMR time-scale (Fig. 2A), according with the KD in the 
low micromolar range18. CSPs were quantified in terms of ΔδHNavs and classified as strong, medium and weak 
(see Methods section for details).
Strong CSP effects on CypA occurred on the sheet β3 (R55) and on the loops β1- β2 (D13), β4-β5 (R69, T73, 
G74), α4-β8 (S153), medium CSPs on the loops α1-β3 (Y48), β4-β5 (T68), α2- β7 (V127) and on the strand β8 
(T157), and weak CSPs on the sheets β3 (H54) and β4 (Q63, G64), the loops β4-β5 (D66, G75), β5-β6 (N102, 
G104, Q111) and α2-β7 (K125, V128, F129) (Fig. 2B). These residues are mapped onto the ribbon structure and 
the surface of CypA (Fig. 2C and D).
Results thus show that residues involved in the interaction are mainly located on a side of CypA protein 
constituted by the loops connecting β-strands, close to the catalytic site of CypA (Fig. 2D). This region is largely 
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characterized by polar and charged residues (Supplementary Fig. S1A), suggesting that hydrophilic interactions 
mostly drive the binding of AIF(370-394) to CypA.
Interestingly, the CypA surface in contact with AIF(370-394) almost entirely overlaps with that covered by the 
full-length protein AIF(Δ1-121), suggesting that the peptide and the protein share the same binding region on 
CypA, according to competition experiments reported in literature18.
NMR-hydrogen/deuterium exchange experiments. A complementary mapping of the AIF(370-
394) binding site on CypA was carried out by performing hydrogen/deuterium (H/D) exchange experiments of 
15N-labeled protein. The protein was thus incubated with and without the ligand in both D2O and H2O, followed 
by the acquisition of 2D 1H-15N HSQC spectra. The intensity of several HSQC cross-peaks of CypA significantly 
increased in the presence of AIF(370-394) compared to those in the isolated protein, as expected when amide 
protons are sequestered into binding sites (Supplementary Fig. S2A and B). Changes were quantified in terms of 
the amide proton protection factors (HN-PF) and plotted versus each residue (Supplementary Fig. S2C and D)19. 
To better evaluate the residues with an increased protection factor, the difference of the HNPFs between the free 
and bound protein in D2O (ΔHN-PF) was calculated, plotted versus the residue number and mapped onto the 
three-dimensional structure of CypA (Fig. 3A and B). A strong effect (ΔHN-PF > 2) was determined for residues 
located in the loops β1-β2 (D13), β3-β4 (G59), β4-β5 (R69, G74, K76, E84, F88), β5-β6 (Q111) and α2-β7 (G124), 
in the helix α3 (N137), and in the loop α3-β8 (K151, K155) (Fig. 3B). As shown in Fig. S3, the ΔHN-PF pattern 
overlaps well with the interaction region identified by CSP studies, confirming the localization of the AIF(370-
394) binding site on the β-sheet surface of CypA. However, there are some residues, including K76, E84, F88, 
G124, N137, K151 and K155, with increased HN-PFs in presence of AIF(370-394) not found in CSP studies. All 
these residues (except N137) belong to loop regions contiguous or proximal to the binding site, suggesting that 
the HN-PFs increase could be due to a reduced conformational flexibility of unstructured regions upon ligand 
interaction. Among these, residues K151 and K155 create a more extended and continuous AIF(370-394) inter-
action surface (Supplementary Fig. S3).
Enzymatic MS-based foot-printing. In order to support NMR results and provide additional experimen-
tal evidences of the interaction surfaces of the CypA/AIF(370-394) complex, we probed the accessible surfaces of 
CypA in the presence and absence of AIF(370-394) by MS analysis. By this approach, ligand-induced protection 
Figure 1. NMR CSP analysis of CypA/AIF(Δ1-121) interaction. (A) Superposition of a 2D [1H, 15N] HSQC 
section of 15N-CypA in the absence (blue) and in the presence of 0.6 equivalents of AIF(Δ1-121) (red). Amide 
cross-peaks with significant intensity reduction are indicated. (B) Bar graphs of the ratio of the intensity of 
CypA in presence of 0.6 eq. AIF(Δ1-121) (Ibound) and free CypA (Ifree) as a function of the amino acid residue. 
The mean value minus 0.5 times the standard deviation (SD) is shown as a continuous line; the mean value 
minus 1 SD as a broken line. The secondary structure elements are also indicated. (C, D) CSP mapping onto 
the representative conformer of the NMR structure of CypA (PDB ID 1OCA)28 shown as ribbon drawing and 
as solvent-accessible surface, respectively. Residues for which Ibound/Ifree is less than the mean minus 1 SD or is 
included between the mean minus 1 SD and the mean minus 0.5 SD are shown in red and in orange, respectively. 
Residues having cross-peaks totally or scarcely visible in the HSQC: C52 (loop α1-β3), F53, H54 (sheet β3), 
G65, T68, H70, N71, G72, E81 (loop β4-β5), G135 (loop β7-α3), were excluded from the CSP analysis and are 
painted in navy on the CypA structure. Pictures C and D were prepared using the software MOLMOL42.
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 1138  | DOI:10.1038/s41598-017-01337-8
against proteolysis is used to map sites stabilized in protein complexes (protein foot-printing)20. Samples of free 
CypA protein and CypA/AIF(370-394) mixtures were subjected to trypsin and chymotrypsin hydrolysis. As 
shown in Fig. 4A, the relative intensity of tryptic peptides I56-R69 (m/z 1541.87, Fig. 4A, upper panel) and 
H126-K131 (m/z 686.35, Fig. 4B, upper panel) was found to be strongly reduced when hydrolyses were performed 
in the presence of AIF(370-394) (Fig. 4A and B, lower panels, respectively). These results indicate that basic 
residues R55 and/or R69 and K125 and/or K131 were protected from proteolysis upon AIF(370-394) binding 
(Fig. 4G and H). However, similarly to what observed for an internal control sequence T32-R37 (Fig. 4F), no 
relative intensity changes were detected for the peptide G50-R55 in the presence of the ligand (Fig. 4E), strongly 
suggesting that R69 is the basic amino acid of the I56-R69 peptide protected upon AIF(370-394) binding. Both 
regions mapped by trypsin MS-based foot-printing fall within the CypA interaction surface identified by NMR 
studies. Moreover, our data are in partial agreement with the 3D molecular model of the CypA/AIF(Δ1-121) 
complex proposed by Candé and coworkers13. Indeed, the tryptic peptide I56-R69 is located within the AIF 
interacting region I predicted by the model (Fig. 4G)13. On the contrary, the region H126-K131 is not included in 
those proposed by the 3D model. Furthermore, for these residues, included in the loop α2-β7, NMR-CSP studies 
Figure 2. Identification of the AIF(370-394) interaction surface on CypA by NMR-CSP studies. (A) 
Superposition of two 2D [1H, 15N] HSQC section of 15N-CypA in the absence (blue) and in the presence 
of different equivalents of AIF(370-394), 1 (red), 2 (green), 5 (yellow) and 10 (magenta), respectively. (B) 
Bar graphs of the average combined chemical shift difference (ΔHNav) as a function of the amino acid 
residue. Mean plus 2 SD, 1 SD and 0.5 SD ΔHNav values are indicated by red, orange and yellow broken lines, 
respectively. The secondary structure elements are also shown. (C, D) CSP data were mapped onto a ribbon 
drawing and solvent accessible surface of the representative conformer of the CypA NMR structure (PDB ID 
1OCA)28 and showed with a color gradient from yellow (weak) to orange (medium) to red (strong). Residues 
having cross-peaks totally or scarcely visible in the HSQC (C52 of the loop α1-β3; G65, H70, N71, G72 of the 
loop β4- β5; G135 of the loop β7-α3) were excluded from the CSP analysis (B) and are painted in navy on the 
CypA structure. Pictures C and D were prepared using the software MOLMOL42.
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indicate that they are weakly perturbed in presence of AIF(370-394), suggesting that they could be not directly 
involved in the interaction but could instead undergo a conformational rearrangement following the interaction 
with AIF(370-394), as recently suggested by a computational and NMR study21.
Additional regions protected from proteolysis were identified by chymotrypsin MS foot-printing. Indeed, 
intensities of consecutive peptides E84-F88 (m/z 652.25, Fig. 4C, upper panel) and K91-L98 (m/z 822.49, Fig. 4D, 
lower panel) were found also strongly decreased in the presence of the peptide ligand. Accordingly, residues 
included in the region E84-F88 resulted strongly protected in the NMR H/D exchange studies, although they were 
not identified by NMR-CSP experiments, as shown above. Also, no residues of segment K91-L98 were identified 
by NMR-CSP and H/D exchange studies. This stretch is located upstream a region containing several amino acid 
identified by NMR analysis, suggesting a possible contribution to the interaction through conformational rear-
rangements, a hypothesis largely corroborated also by the studies of Doshi et al., indicating a relevant structural 
flexibility in this region upon perturbation by substrate binding or distant mutations21. In addition, this region is 
included in region II (H92-A101) suggested by the predicted molecular model of Candè et al.13. Further experi-
ments are described below to clarify this specific point.
Design and testing of CypA-derived synthetic peptides. NMR and MS data have shown that the AIF 
binding region on CypA is extensive and discontinuous. To gain further insights on the CypA regions mostly 
involved in the interaction with AIF, a set of overlapping CypA-peptides was generated and tested for binding 
against the protein and the AIF(370-394) fragment. Although peptide-peptide interaction insights might be prej-
udiced by the lack of appropriate 3D structures and require additional experimental assessment with full length 
proteins, they can mimic and anticipate in several cases real interactions22. The binding affinity toward AIF(370-
394) was thus assessed through direct binding assays using the EnSpire-label free system (see Supplementary 
Information for details)23. KD values determined by this approach are reported in Table 1 and the binding curves 
are shown in Supplementary Fig. S4. Remarkably, most of CypA-derived peptides provided a KD in the low 
Figure 3. Identification of the AIF(370-394) interaction surface on CypA by NMR-H/D exchange studies. (A) 
Bar graphs of the difference of the HN-PFs between the free and bound protein (ΔHN-PF) as a function of the 
amino acid residue. The broken line traced at ΔHN-PF = 2 is used as threshold to identify the protected amides 
upon binding. (B) Amide hydrogens of residues showing ΔHN-PFs higher than 2 were represented as balls 
in magenta onto the ribbon drawing of the representative conformer of the NMR structure of CypA (PDB ID 
1OCA)28. (C) Comparison of the ΔHN-PF and CSP patterns by mapping on the amino acid sequence of CypA. 
Residues affected upon AIF(370-394) binding both by the H/D exchange and by the CSP studies are shown in 
blue; residues identified by CSP or H/D exchange studies are shown in red and in magenta, respectively.
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micromolar range, which is comparable to that of the full length CypA/AIF(370-394) complex18. Among these 
peptides, CypA(55-69) exhibited the strongest affinity for AIF(370-394) (KD = 6.3 ± 0.1 μM). Furthermore, a sig-
nificant positive effect in terms of KD was observed by combining peptides CypA(55-69) with the lower affinity 
N-terminal overlapping peptide, CypA(49-62). In addition, when CypA(67-79) was tested in combination with 
the peptide CypA(49-62), distant in the primary sequence but in close proximity in the tertiary structure, a sig-
nificant increase of affinity for AIF(370-394) was detected. This finding further confirmed the importance of the 
CypA region encompassing residues K49-Y79, belonging to loops α1-β3, β3-β4 and β4-β5, in the interaction with 
the AIF peptide.
Peptides deriving from region 83–150 showed an affinity for AIF(370-394) lower than that of CypA(55-
69), suggesting a minor involvement of this region in the interaction (Table 1 and Figure S4 in the Supporting 
Information). Among the peptides from this region, CypA(121-131) appeared as the best binder with a KD of 
about 24 μM. Moreover, the combination of CypA(121-131) with CypA(83-90) and CypA(99-109), covering the 
C-terminal portion of loop β4-β5, and strand β5 did not provide an increase of affinity for CypA. This observa-
tion, together with data on protein dynamics, suggested that region 83–150 may contain a second lower affinity 
binding site across residues 121–131 and that residues 95–110, upon AIF binding, may undergo a significant 
allosteric rearrangement due to the intrinsic conformational flexibility of the protein in this region21.
Peptides CypA(3-27), CypA(136-150), designed on the basis of the previous model of the AIF(Δ1-121)/CypA 
complex13, and CypA(154-165), did not interact with AIF(370-394), in agreement with MS data (Supplementary 
Fig. S4).
CypA-derived peptides were also tested against AIF(Δ1-121) protein (Table 1 and Supplementary Fig. S5). 
Noteworthy, a very good correlation was observed between the KDs measured for AIF(370-394) and AIF(Δ1-
121). An overall significant increase in the CypA-AIF(Δ1-121) affinity was observed for peptides CypA(3-27), 
CypA(99-109) and CypA(49-62) (Table 1), suggesting that additional interactions, outside the 370–394 region, 
stabilize the complex with AIF(Δ1-121).
To dissect the relative contributions of crucial residues of CypA to the binding with AIF, a series of mutated 
CypA-peptides were synthesized. KD values are reported in Table 1 and binding curves in Supplementary Figs S4 
and S5.
In particular, residues R55, T68 and R69, supposed to play a key role in the interaction between CypA(55-69) 
and AIF(370-394) by NMR data, were replaced by alanine. Data show that the affinity of the alanine variants 
for AIF(370-394) and AIF(Δ1-121) was largely reduced, confirming the importance of these residues in the 
Figure 4. MALDI-TOF spectra of tryptic (A, B) and chymotryptic (C, D) CypA peptides protected from 
proteolysis following hydrolyses performed in the absence (upper panel) and in the presence (lower panel) 
of AIF(370-394) peptide. Representative CypA control peptides for which no relative intensity changes 
were detected are reported in (E) (sequence region 50-55) and (F) (sequence region 32-37). (G) Tryptic and 
chymotryptic peptides protected from proteolysis in the presence of AIF(370-394) peptide are grey shaded on 
CypA sequence. Amino acids identified by CSP-NMR and/or H/D-exchange are reported in blue. Moreover, 
the regions I-IV identified by Candé et al.13 are indicated on the sequence. Control tryptic peptides showed in 
E, F are boxed. (H) Tryptic and chymotryptic peptides protected from proteolysis in the presence of AIF(370-
394) peptide and amino acids in the close proximity of these peptides are also highlighted in the CypA structure 
(PDB ID 1OCA)28 in blue and pink, respectively.
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recognition. In particular, replacement of R69 of CypA with alanine completely abrogated the binding to both 
the AIF forms, the R55 replacement completely abrogated the affinity with AIF(370-394), and slightly reduced 
that with AIF(Δ1-121), whereas T68 replacement decreased the affinity by 7- and 10-fold for AIF(370-394) and 
AIF(Δ1-121), respectively.
Altogether, data demonstrate that the interaction site of AIF(370-394) on CypA is close to its catalytic site and 
partially interacts with the CsA-binding residues and in particular with the catalytic residue R5524.
However, several evidences demonstrate that CsA binding on CypA does not prevent the interaction with 
AIF(Δ1-121)13 (see also Supplementary Fig. S6) and that the lethal activity of the AIF(Δ1-121)/CypA complex 
is completely independent from the PPIase activity of CypA13. Also, the binding of AIF(370-394) to CypA does 
not alter the catalytic activity of CypA18. To strengthen this concept we measured the affinity of the R55A CypA 
mutant (CypAR55A) for AIF peptide and protein by EnSpire-label free techniques23. As shown in Fig. S7A and B, 
AIF(370-394) and AIF(Δ1-121) bound CypA and CypAR55A in a similar way suggesting that, although R55 does 
interact with the peptide to some extent, its role in the interaction is very limited.
On the other hand, the inability of the AIF(370-394) peptide to inhibit the cis-trans prolyl peptidyl isomerase 
activity of CypA can be justified by the generally higher affinity of CypA for its catalytic substrates. We have tested 
this hypothesis using a CypA peptide substrate25 and performing binding experiments between wild type and 
R55A mutant protein and the substrate in the presence and absence of the AIF(370-394) and CsA. Data showed 
that, in line with the large difference in affinity (57 nM for the substrate and 6 μM for the AIF peptide), AIF(370-
394), used at a 10-fold excess, is unable to prevent the binding of both CypA and CypAR55A to the substrate, but 
recognition is abolished in the presence of the strong inhibitor CsA (Supplementary Fig. S8). Remarkably, bind-
ing of the substrate in the presence of larger excess of AIF(370-394) does impair the enzyme-substrate recognition 
(not shown).
Furthermore, a substitution of the catalytic residue H12624 in CypA(121-131) with alanine, as expected from 
the CSP-data, did not affect significantly CypA binding for both the peptide and the full-length protein, further 
remarking the concept that the CypA catalytic pocket is not involved in the interaction with AIF.
Thermodynamic studies. This tricky issue was further evaluated by the analysis of the interactions of 
CypA with both AIF(370-394) and CsA by ITC. Data show that the binding of AIF(370-394) to CypA is exother-
mic, resulting in negative peaks in the plots of power versus time (Fig. 5A, upper panel). Signals well fit with a 
single-site binding model and allow the determination of the KD, and of enthalpy (ΔH) and entropy (ΔS) changes 
associated to the interaction (Fig. 5A, lower panel). Data also show that AIF(370-394) binds CypA with a KD of 
about 6 μM, in good agreement with the value estimated by SPR18. Moreover, ITC data show that the interaction 
is enthalpically driven although there is a slight positive entropic contribution (Table 2). This finding reflects the 
Peptides
AIF(370-394) KD 
(μM)
AIF(Δ1-121) KD 
(μM)
CypA(3-27) >103 4.2 ± 1.2
CypA(49-62) 123 ± 5.8 25.9 ± 4.2
CypA(55-69) 6.3 ± 1.0 10.3 ± 1.6
CypA(67-79) >103 47.3 ± 6.7
CypA(83-90) No binding No binding
CypA(99-109) >103 26.5 ± 2.8
CypA(121-131) 18.4 ± 1.8 19.3 ± 1.6
CypA(136-150) No binding No binding
CypA(154-165) No binding No binding
CypA(55-69) + (67–79) 34.9 ± 8.1 51.4 ± 12.2
CypA(55-69) + (49–62) 4.6 ± 1.3 2.2 ± 0.7
CypA(67-79) + (49–62) 3.1 ± 1.3 2.8 ± 0.9
CypA(55-69) + (67–
79) + (49-62) 20.7 ± 6.5 25.2 ± 5.0
CypA(121-131) + (99–
109) 43 ± 6.8 27.2 ± 5.8
CypA(121-131) + (83–
90) 87 ± 5.8 31.3 ± 2.8
CypA(99-109) + (83–90) 304 ± 10.8 No binding
CypA(121-131) + (99–
109) + (83-90) 268 ± 9.65 38.8 ± 4.6
CypA(55-69)R55 No binding 42.1 ± 9.8
CypA(55-69)T68 41.5 ± 9.65 43.2 ± 8.8
CypA(55-69)R69 No binding >103
CypA wild type 3.0 ± 0.60 1.6 ± 0.1
CypAR55A 3.1 ± 0.70 1.6 ± 0.2
Table 1. Comparison of AIF(Δ1-121) and AIF(370-394) binding affinities for the CypA peptides studied.
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contributions of Van der Waals, hydrogen bond, and electrostatic interactions to the binding, in agreement with 
the mainly polar and charged features of the AIF(370-394) binding surface.
By ITC, we estimated a KD value of 0.6 μM for the interaction between CypA and CsA (Fig. 5B). In agreement 
with previous reports, the binding is underpinned by a stoichiometry of 1:1, is entropically unfavorable and is 
entirely driven by the exothermic binding enthalpy26. By comparing the ITC data related to the two interactions, 
we notice some interesting features. Beside the remarkable difference in free energies (ΔG) that reflects the sig-
nificant difference in KD values (Table 2), we also note that the binding enthalpy for AIF(370-394) is 10 kcal/
mol lower than that of CsA. This difference can be attributed, at least in part, to a greater number of H bond and 
Van der Waals interactions present in the CypA/CsA complex compared to that formed by CypA and AIF(370-
394). Such a difference yields a larger entropic loss in the case of CsA binding (Table 2), indicating that the heat 
release is accompanied by a strong loss of disorder mostly due to the conformational restriction of the ligand 
backbone in the cavity. On the contrary, the entropy gain observed in the AIF(370-394)/CypA association might 
be attributed to a significant electrostatic steering and to a substantially unaltered conformational freedom of 
Figure 5. ITC binding assay. (A, B) Calorimetric titration of AIF(370-394) and CsA with CypA, respectively. 
The top panels show the heat signal for AIF(370-394) (A) and CsA (B) injections into a cell containing CypA 
at 25 °C. The bottom panels show the integrated heat of each injection after correction for the heat of dilution 
of ligands. Curves represent the best fit to a single-site binding model. (C, D) ITC competition assays. (C) 
Calorimetric titration of the preformed complex CsA-CypA with AIF(370-394). The top panel shows the heat 
signal for AIF(370-394) injections into a cell containing CypA/CsA complex at 25 °C. (D) Calorimetric titration 
of the AIF(370-394) - CypA complex with CsA. The top panel shows the heat signal for CsA injections into a 
cell containing CypA/AIF(370-394) complex at 25 °C. (E) Bar graphs of the ΔHNav as a function of the amino 
acid residue upon addition of AIF(370-394) to the free CypA (black) and the complex CypA/CsA (gray).
Single Site Binding Model
Nα ΔGβ ΔHβ TΔSβ KDγ
CypA-AIF(370-394) 1.0 −7.3 −6.2 1.1 6
CypA-CsA 1.0 −17.8 −29.6 −11.8 0.6
CypA + AIF(370-394)/
CsA 1.4 −14.5 −14.7 −0.2 1.8
Table 2. Thermodynamic parameters associated with the binding of CypA with CsA and AIF(370-394). 
αNumber of binding site, βExpressed in kcal/mol, γExpressed in μM.
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the ligand following complex formation, deriving from the reduced affinity and binding interface intervening 
between AIF(370-394) and CypA.
In competition experiments, when AIF(370-394) was titrated onto the CypA-CsA preformed complex, 
no apparent heat exchange was observed in a AIF(370-394) concentration range spanning from 5 to 500 μM 
(Fig. 5C). On the contrary, when CsA was added to the CypA/AIF(370-394) complex, robust heat changes were 
observed (Fig. 5D). The binding isotherm for CsA, derived from the integrated heat data, could be fitted by a 
model of a single binding site with an apparent dissociation constant of 1.6 ± 0.5 × 10−6 M. Such observations 
suggest that AIF(370-394) is unable to bind CypA in the presence of CsA, a stronger CypA ligand, while CsA 
binds CypA displacing AIF(370-394), in agreement with the idea of partially overlapping binding sites. Moreover, 
the ligand-binding measurements are consistent with a negative cooperation model in which the CsA affinity for 
CypA is weaker in the presence of AIF(370-394).
To explore in more detail this aspect we performed NMR competition experiments in which AIF(370-394) 
was gradually added to the preformed CypA/CsA complex. As shown in Fig. 5E, CsA binding to CypA did not 
fully abrogate the AIF(370-394) interaction with CypA. However, occupancy of the binding site by CsA makes 
inaccessible V127 and the crucial residue R55. Overall, data indicate that R55 is not crucial for the interaction 
between CypA and the peptide.
Docking model of the AIF(Δ1-121)/CypA complex. Data were used to generate an experimentally 
driven structural model of the AIF(Δ1-121)/CypA. CSP data from NMR titration experiments between CypA 
and AIF(Δ1-121) proteins were employed to define a set of active and passive residues for HADDOCK calcula-
tions27. In addition, residues of the region 370-394 of AIF(Δ1-121) exposed to the solvent in the crystal structure, 
were used to restrict the interaction interface of AIF(Δ1-121).
The docking calculations generated 100 solutions that were sorted into 12 clusters based on the HADDOCK 
score. The best 4 structures of clusters with negative Z-Score were visually inspected. The first cluster with the 
lowest HADDOCK score was the most populated (46 structures) and resulted more in line with experimental 
data. The best structure of the first cluster chosen as the representative model of the AIF(Δ1-121)/CypA complex, 
is shown in Fig. 6.
In this model, which is consistent with structural and biochemical data, main interactions involve loops 
α1-β3 (G42-C52) and β4-β5 (G65-S99) of CypA. These regions establish contacts with AIF residues 370-392, 
in agreement with binding studies. In particular, R69 provides a crucial contribution to the binding, establishing 
hydrogen bond and Van der Waals interactions with V374 and S375 of AIF(Δ1-121), in line with NMR, MS and 
binding studies using the Ala-mutated CypA-peptides. Furthermore, CypA residues showing exchange contri-
bution, such as C52, T68, H70 (coloured in royal blue in Figs 1 and 2)28 were directly involved in the interaction 
with AIF(Δ1-121).
Our interaction model also explains the difference of affinity displayed by CypA(3-27) for AIF(Δ1-121) and 
AIF(370-394) (see Table 1). Indeed, additional contacts are predicted between residues of the CypA loop β1-β2 
(D13-G14) and of AIF(Δ1-121) not included in the 370-394 region, such as E329 (strand β12), K362 (strand 
β13), together with D392 (loop β16-β17) (Fig. 6).
Residues of the loop β5-β6, sheet β6 and loop β6-α2 (A101, N102, A103, S110, Q111, C115, T119) are not 
directly involved in the AIF binding site on CypA in the representative model, though these residues, identified 
in NMR-CSP experiments, could be indirectly affected by AIF binding. Among the other solutions provided by 
HADDOCK, there is an interaction model in which CypA contributes to the binding also with these residues, 
Figure 6. Molecular docking studies. Model of CypA/AIF(Δ1-121) complex provided with the lowest/best 
Haddock score. The binding regions and side chains of binding residues of CypA and AIF are indicated in violet 
and royal blue, respectively.
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suggesting an additional, lower-affinity, binding site of AIF(Δ1-121) on CypA, close to loops α1-β3 and β4-β5, 
the primary site recognized by AIF(Δ1-121).
Interestingly, the complex most representative model shows R55 of CypA as not included in the binding inter-
face, suggesting slight differences between AIF(Δ1-121) and AIF(370-394) binding mode on CypA.
Our experiment-based docking model of the AIF/CypA complex delineates a new interaction surface for 
AIF(Δ1-121) on CypA. This site represents a new specific druggable region of CypA, beside the catalytic pocket. 
Indeed, a computational analysis of druggable sites on CypA using the FTMap algorithm (see Supporting 
Information for details)29, showed that loops α1-β3 (G42-C52) and a portion of loop β4-β5 (G65-S99), delimit a 
region with high chances to host ligands with low-micromolar affinity (Supplementary Fig. S9).
Discussion
The CypA/AIF(Δ1-121) complex is considered a very promising target for compounds with neuroprotective 
activity8–18. Therefore, understanding the molecular mechanism underpinning the CypA/AIF(Δ1-121) recogni-
tion may have a broad impact on the development of novel molecular therapies for neurodegeneration.
In this study, we provide the first structural and biophysical characterization of the CypA/AIF(Δ1-121) inter-
action. We have used both the AIF(Δ1-121) protein and the synthetic peptide encompassing region 370-394, 
which binds CypA and has been successfully utilized for elucidating the biological implication of CypA in the 
AIF-mediated neuronal cell death18.
The binding surface of AIF(Δ1-121) on CypA, mainly includes loops α1-β3 (G47, S51), β4-β5 (F67, R69, T73, 
G74, K76, I78, K82, E86, G96) and β5-β6 (A101, N102, S110, Q111). This surface contains, almost entirely, the 
interaction region of the AIF(370-394) peptide on CypA, in agreement with the peptide’s ability to prevent the 
CypA/AIF(Δ1-121) binding, and confirming that it might be used as a simplified model to study the interaction.
Interestingly, the identified interaction surface, partially overlap with the catalytic and CsA binding sites on 
CypA. Moreover, somewhat unexpectedly, for the peptide we found that it interacts with the highly conserved 
CypA catalytic residue R55, which is also engaged by CsA24. However, unlike CsA, AIF(370-394), as well as 
AIF(Δ1-121), does not impair the catalytic activity of CypA13, 18. Additional data obtained with the R55A mutated 
CypA demonstrate that the interaction of the peptide with the catalytic residue is of limited importance compared 
to CsA and to CypA substrates, since recognition is substantially retained in the mutated protein and peptide 
binding is prevented in the presence of strong interacting substrates. This observation clearly indicates that R55 is 
not required for efficient recognition of the two proteins but incidentally interacts with the AIF(370-394) peptide 
because of its higher flexibility.
Our studies also demonstrate that the CypA region spanning residues G50-R69, are those most involved in the 
interaction with AIF, and that residue R69 is crucial for complex formation, delineating the recognition surface of 
AIF(Δ1-121) on CypA. The identification of these residues provides new insights for the design of new AIF-based 
peptides or small molecules that have the potential to inhibit the AIF pro-apoptotic action.
The structural information we have gained by mapping the binding surface of AIF(Δ1-121) on CypA by NMR 
experiments, enables us to propose a new model representative of the AIF(Δ1-121)/CypA complex (Fig. 6). By 
this model CypA binds AIF(Δ1-121) in a hydrophilic region, very close to the catalytic and CsA binding site 
including loops α1-β3 (G42-C52) and β4-β5 (G65-S99). The proposed CypA binding interface accommodates 
very well residues included in the AIF region 370-394, but further extends to E329 on strand β12 and K362 on 
strand β13, which are spatially close and exposed on the protein surface (Fig. 6)28. In this model CypA residue 
R69 is crucial for the recognition, establishing hydrogen bond and Van der Waals interactions with V374 and 
S375 of AIF(Δ1-121), in agreement with NMR, MS and binding studies. This should be one of the most impor-
tant hot spots for structure-based drug design.
The model proposes that the catalytic residue R55 of CypA is not directly involved in the interaction with full 
length AIF and that the interaction of residues 370-394 of AIF with CypA is slightly different when they are in the 
isolated peptide or embedded in the protein architecture. This is in agreement with evidences from NMR-CSP 
and binding experiments. Indeed, no cross-peak for R55 are observed during NMR titration experiments with 
the proteins, whereas strong perturbations are observed using the synthetic peptide AIF(370-394). We also find 
that replacement of R55 with alanine in CypA(55-69) completely abrogates the affinity with AIF(370-394), while 
it only slightly reduces that with AIF(Δ1-121). Data are not surprising as the isolated CypA peptide, because of 
its higher flexibility in solution, might show an incidentally increased ability to bind the peptide.
Some CypA regions suggested by our data as potential sites of recognition for AIF, do not fit with this model. 
However, additional contacts have been suggested by the docking computational solutions, like the one involving 
loop β5-β6 (A101, N102, S110, Q111) of CypA. On the basis of this evidence, we speculated that this region could 
be a second binding site for AIF, with a weaker affinity compared to that involving α1-β3 and β4-β5. However, 
NMR data can be explained by an allosteric effect of this region upon the AIF binding. Indeed, this area falls 
within the “dynamic cluster” recently proposed by Doshi et al.21, by NMR and molecular dynamic studies on 
CypA. In particular, they found that the substrate binding in the catalytic cleft provides strong dynamic contacts 
in regions distal from the site, spanning residues 85-150, and only limited effects in the active site region. Our 
NMR results then provide further experimental evidence on the binding mode of CypA, probably at the basis of 
the promiscuity of the enzyme.
In conclusion, our structural and biochemical studies afford the first experimental insights underlying the 
AIF(Δ1-121) and AIF(370-394) binding to CypA and identifies region 55-69 of CypA as the most involved in 
the protein-protein interaction. It also provides an explanation of why the peptide and the protein do not inhibit 
the cis-trans peptidyl-prolyl-isomerase activity of CypA. Our data also suggest the occurrence of a second lower 
affinity site around residues 121-131 and that AIF binding induces a conformation rearrangement on the most 
flexible residues 95-115.
www.nature.com/scientificreports/
1 1Scientific RepoRts | 7: 1138  | DOI:10.1038/s41598-017-01337-8
Methods
Peptide synthesis. Peptides were synthesized, purified and characterized as described previously30. Peptide 
concentrations, missing of Trp and Tyr residues, were determined via the Scopes method in which the absorb-
ance of the peptide bond at 205 nm is monitored by using a NanoDrop200c UV-Vis spectrophotometer (Thermo 
Scientific)31.
Protein preparation. His-tagged CypA (hereafter CypA) and the corresponding R55A mutant, were 
expressed and purified as previously reported25. The protein concentration was determined by reading the absorb-
ance at 280 nm with a NanoDrop200c UV-Vis spectrophotometer and using a theoretical molar extinction coeffi-
cient of 8730 M−1cm−1. 15N-labeled protein was prepared by growing bacteria in a minimal medium with 15NH4Cl 
(Sigma Aldrich) as the sole nitrogen source, following indications reported in literature28. In particular, a single 
clone of CypA strain was cultured for 16 h at 37 °C in 50 mL of LB medium with antibiotics. The harvested cells 
were centrifuged for 15 min at 5000 rpm and suspended in 10 mL of M9 medium. Subsequently a spectrophoto-
metric reading of cells was carried out to determine the start value of OD600nm, (generally 0.15 ÷ 0.18 absorbance). 
Cells were then inoculated in M9 medium containing 15NH4Cl (Sigma Aldrich 1 g/L) as the sole nitrogen source, 
and grown at 37 °C. For the overexpression, cells were grown at 37 °C till the mid log phase (OD600 = 0.9 ± 0.5 
absorbance). At this point the expression was induced by addition of IPTG (1 mM). Cells were allowed to grow 
for further 15-16 hours at 25 °C. After harvesting, cells were lysed and 15N-6His-CypA (hereafter 15N-CypA) was 
purified by affinity chromatography on a His-trap HP column, followed by a step of size exclusion chromatog-
raphy. CypAR55A was prepared starting from the construct pCMV6-AC-Myc-CypAR55A kindly provided by the 
group of Dr. Valentina Bonetto of the Department of Molecular Biochemistry and Pharmacology-IRCCS “Mario 
Negri”, Milano, Italy.
Isothermal Titration Calorimetry (ITC) experiments. ITC experiments were performed at 25 °C using 
a MicroCal ITC200 (GE Healthcare Bio-Sciences AB, Sweden). Protein and peptide samples were dialyzed in 
phosphate saline buffer (PBS 1X) containing 1 mM DTT, pH 7.4. In each titration, 20 injections of 2 μL each of 
AIF(370-394) at 0.7 mM peptide were performed on a sample of 300 μL of CypA at 5 μM. For CypA-CsA experi-
ments, 300 μL of a 20 μM solution of CypA were titrated by adding 2 μL aliquots of a 2 μM CsA solution at 25 °C in 
PBS buffer containing 0.1% DMSO. Data were analyzed using the “Origin” software (MicroCal). The dissociation 
constant (KD), molar binding stoichiometry (n) and the binding enthalpy (ΔH), entropy (ΔS) and Gibbs free 
energy (ΔG) were determined by fitting the binding isotherm to a one-site model with MicroCal Origin software. 
All ITC experiments were performed in triplicate.
NMR spectroscopy. NMR experiments were carried out following procedures previously reported32. In par-
ticular, experiments were developed at 25 °C using an Inova 600 MHz spectrometer (Varian Inc., Palo Alto, CA, 
USA), equipped with a cryogenic probe optimized for 1H detection. NMR samples were concentrated to 400 µM 
for the assignment of backbone amide in PBS pH 5.8 and ~80 μM for HSQC-based titration experiments in PBS 
pH 5.8 or 20 mM Tris-d11, 100 mM NaCl with 10% D2O and 0.02% NaN3, pH 7.2. NMR data were processed 
by the software VNMRJ 1.1.D (Varian Inc.). One-dimensional (1D) spectra were analyzed using ACD/NMR 
Processor 12.0 [ACD/NMR]; two and three-dimensional (2D and 3D) spectra were analyzed using tools available 
in CARA (Computer Aided Resonance Assignment) software (downloaded from cara.nmr.ch)33.
Almost complete HN and N resonance assignments of 15N-HSQC-detected residues of CypA were achieved, as 
previously reported34, based on 3D 15N-edited NOESY35 and 15N-edited TOCSY spectra36, acquired with a mixing 
time of 80 and 50 ms, respectively, in combination with previous assignments reported in literature37. The indole 
HN group of the single Trp residue was unambiguously assigned. To characterize the AIF binding site, intensity 
reduction of the amide cross-peaks in the CypA 15N-HSQC spectrum was evaluated calculating the following 
ratio: Ibound/ Ifree38, 39 for each residue having well visible cross-peaks in the HSQC spectrum of the free CypA. 
Ifree and Ibound are, respectively, the amide cross-peak intensities in the absence and in the presence of AIF at 1:0.6 
ratio CypA:AIF(Δ1-121). Lower than the mean value minus 1 SD and 0.5 SD were identified as most significative 
changes of signal intensities and mapped on the three-dimensional structural of CypA according to a color code 
(Fig. 1). To define the AIF(370-394) binding site, 2D 1H-15N HSQC spectra were recorded on 15N-CypA (80 μM) 
in the presence of increasing concentrations of AIF(370-394) peptide ranging from 0 to 800 μM in PBS buffer, 
pH 5.8. The chemical shift perturbation (CSP) was quantified by average combined chemical shifts between the 
free form and AIF(370-394)-bound CypA protein using the following equation: ΔδHNav = [((ΔδHN)2 + (ΔδN
/5)2)/2]1/2 where ΔδH and ΔδN are the chemical shift variations of the amide proton and nitrogen resonances, 
respectively. Strong, medium and weak CSPs were classified as ΔδHNav > mean + 2 SD, mean + 1 SD < ΔδHNav 
< mean + 2 SD and mean + 0.5 SD < ΔδHNav < mean + 1 SD, respectively.
NMR-H/D exchange experiments. For NMR H/D exchange experiments, a sample of ~200 μM of 
15N-CypA in the absence and in the presence of AIF(370-394) (1:10 molar ratio) was lyophilized from PBS at 
pH 6.3. Lyophilized samples were first dissolved in 100 μL H2O (to avoid potential refolding artifacts) and then 
in 400 μL D2O. Samples were quickly transferred to a 5 mm NMR tube and fast 1H-15N HSQC spectra (time 
~10 min) were collected after 7 min from D2O addition. A control experiment was run in which a sample of 
200 μM of 15N-CypA in PBS at pH 6.3 was first lyophilized and then dissolved in 500 μL of H2O.
Amide proton protection factors were determined for both the free and bound protein by calculating the 
ratios of the intensities of the CypA HSQC cross-peaks after H/D exchange and in H2O (HN-PF = IH2O/ID2O). 
Then, the difference of the HN-PFs between the bound and free protein (ΔHN-PF = HN-PFbound - HN-PFfree) was 
determined19. Residues of CypA, whose ΔHN-PF are higher than 2, were considered as buried upon AIF(370-
394) binding.
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Enzymatic MS-based foot-printing. For MS-based foot-printing analyses, tryptic hydrolyses were per-
formed by adding TPCK-treated trypsin (1 µg/µL) to aliquots (300 pmol) of CypA (15 µM) in the presence of 
AIF(370-394) (300 µM) at an enzyme/substrate ratio of 1:50 (w/w) in a final volume of 20 µL, incubating mixtures 
at 37 °C for 2 h. The same amount of CypA without AIF(370-394) and the peptide alone were also digested as 
control samples. Protein digestions were blocked by adding 80 µL of aqueous 0.1% TFA. Chymotryptic hydrolyses 
were performed as described above by adding TLCK-treated chymotrypsin at an enzyme/substrate ratio of 1:250 
(w/w) and by incubating the mixtures at 37 °C for 2 h. Following enzymatic digestions, samples were centrifuged 
(15800 g, 15 min). For matrix assisted laser desorption ionization time-of-flight (MALDI-TOF) MS analyses, an 
internal standard peptide (molecular mass at m/z 620.36) for spectra normalization was added to mixtures (5:1) 
and 1 μL of diluted samples was mixed with 1 μL of saturated α-cyano-4-hydroxycinnamic acid matrix solution 
(10 mg/mL in acetonitrile/water (1:1, v/v), containing 0.1% trifluoroacetic acid). Thus, a droplet of the resulting 
mixture (1 μL) was placed on the MALDI-TOF micro MX (Waters, Manchester, UK) target plate and dried at 
room temperature. Once the liquid was completely evaporated, samples were loaded into the mass spectrometer 
and analyzed. The instrument was externally calibrated using a tryptic alcohol dehydrogenase digest (Waters) in 
reflectron positive ion mode40. All spectra were processed and analyzed using the MassLynx 4.1 software. Relative 
intensity decrease was considered as significant when at least a 1.5 fold change was observed.
Molecular docking studies. Docking calculations of CypA and AIF(Δ1-121) were performed by the 
HADDOCK webserver23. The structural coordinates of CypA and AIF(Δ1-121) used as the input were obtained 
from the most representative NMR structure (model 6, PDB ID: 1OCA)28 and from the crystal structure (PDB 
ID: 1M6I)41, respectively. CypA active residues were assigned from CypA-AIF(Δ 1-121) CSP NMR studies (D13, 
G14, R19, G47, S51, F67, R69, T73, G74, K76, I78, K82, E86, G96, M100, A101, N102, S110, Q111, C115, T119, 
K133, M136, N137, S153). AIF residues of the region 370-394 of AIF(Δ1-121), exposed to the solvent in the crys-
tal structure, were used to define the AIF active residues (Q370, S371, S375, S376, G377, K378, L380, K382, K384, 
D385, G386, R387, K388, E390, D392, H393). Passive residues were automatically selected for both proteins by 
the HADDOCK web server27. Default HADDOCK parameters were used throughout the docking calculations. 
During the rigid body energy minimization 1000 structures were generated. Then the 200 lowest energy struc-
tures were used for semi-flexible simulated annealing and explicit water-refinement. Clustering of the final 200 
structures was performed by the HADDOCK web server. The complex structures were analyzed by MOLMOL42.
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